Annex Advisory Services LLC Buys 24,750 Shares of Intuitive Surgical, Inc. $ISRG

Annex Advisory Services LLC lifted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 37.4% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 90,943 shares of the medical equipment provider’s stock after purchasing an additional 24,750 shares during the quarter. Annex Advisory Services LLC’s holdings in Intuitive Surgical were worth $36,166,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the stock. State Street Corp lifted its position in Intuitive Surgical by 1.0% in the fourth quarter. State Street Corp now owns 15,701,591 shares of the medical equipment provider’s stock worth $8,892,753,000 after buying an additional 162,264 shares during the last quarter. Capital World Investors increased its position in Intuitive Surgical by 1.7% during the fourth quarter. Capital World Investors now owns 7,856,018 shares of the medical equipment provider’s stock valued at $4,449,491,000 after acquiring an additional 127,526 shares during the last quarter. Norges Bank bought a new position in Intuitive Surgical during the fourth quarter valued at $2,856,987,000. Invesco Ltd. raised its stake in shares of Intuitive Surgical by 17.4% in the fourth quarter. Invesco Ltd. now owns 4,128,735 shares of the medical equipment provider’s stock valued at $2,338,350,000 after acquiring an additional 611,268 shares during the period. Finally, Bank of America Corp DE raised its stake in shares of Intuitive Surgical by 3.3% in the first quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock valued at $1,667,388,000 after acquiring an additional 116,292 shares during the period. Institutional investors own 83.64% of the company’s stock.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive Surgical’s second-quarter results exceeded expectations: revenue rose 18.4% year over year to $2.89 billion, while EPS reached $2.80 versus the $2.48 consensus estimate. Higher margins, continued adoption of its da Vinci and Ion platforms, and long-term demand for robotic-assisted surgery support the bullish case. Intuitive Surgical Just Beat Earnings
• Positive Sentiment: A bullish investor cited Intuitive Surgical’s potential once-per-decade hardware replacement cycle and approximately $8.6 billion cash position, arguing that the more than 30% year-to-date decline could create an attractive long-term entry point. The Number One Reason I Keep Buying Intuitive Surgical
• Neutral Sentiment: Analyst sentiment remains broadly favorable, with a “Moderate Buy” consensus and an average price target of $509.02. However, several firms recently lowered their targets, reflecting greater caution after the earnings report.
• Neutral Sentiment: Reported short interest was zero shares, implying no measurable short-selling pressure. The figure appears unusual and may reflect incomplete or unreliable data rather than a meaningful market signal.
• Negative Sentiment: Despite the earnings beat, investors remain concerned about slowing domestic procedure growth and whether the company’s roughly 46 P/E adequately reflects its growth prospects. Those concerns have contributed to the stock’s recent weakness. Intuitive Surgical Earnings and Valuation Analysis
• Negative Sentiment: Director Amy L. Ladd sold 472 shares across August 10–11, reducing her holdings by a substantial percentage, while EVP Gary Loeb sold 400 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, which reduces their significance as a discretionary bearish signal but may still weigh modestly on sentiment.

Intuitive Surgical Stock Up 2.0%

Shares of NASDAQ ISRG opened at $401.23 on Wednesday. Intuitive Surgical, Inc. has a twelve month low of $328.57 and a twelve month high of $603.88. The firm has a market cap of $141.75 billion, a PE ratio of 45.96, a price-to-earnings-growth ratio of 2.84 and a beta of 1.46. The business has a fifty day simple moving average of $392.47 and a two-hundred day simple moving average of $443.35.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.48 by $0.32. The business had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $2.83 billion. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%.The business’s revenue was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.81 EPS. On average, research analysts expect that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current year.

Analysts Set New Price Targets

ISRG has been the subject of a number of recent analyst reports. UBS Group started coverage on shares of Intuitive Surgical in a research note on Tuesday, July 28th. They set a “neutral” rating and a $500.00 price target for the company. Raymond James Financial reissued an “outperform” rating and issued a $483.00 price objective (down from $577.00) on shares of Intuitive Surgical in a research report on Friday, July 17th. The Goldman Sachs Group set a $558.00 price objective on shares of Intuitive Surgical in a research note on Wednesday, May 27th. Leerink Partners dropped their target price on Intuitive Surgical from $573.00 to $454.00 and set an “outperform” rating for the company in a research report on Friday, July 17th. Finally, Wells Fargo & Company restated an “overweight” rating and set a $487.00 target price (down from $654.00) on shares of Intuitive Surgical in a research report on Friday, July 17th. Twenty investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $509.02.

Insider Buying and Selling

In other Intuitive Surgical news, Director Amy L. Ladd sold 72 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $393.10, for a total transaction of $28,303.20. Following the transaction, the director directly owned 179 shares in the company, valued at $70,364.90. This represents a 28.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Iman Jeddi sold 5,625 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $420.55, for a total transaction of $2,365,593.75. Following the transaction, the senior vice president directly owned 6,463 shares in the company, valued at $2,718,014.65. This trade represents a 46.53% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 7,106 shares of company stock valued at $2,949,518 over the last three months. 0.60% of the stock is owned by company insiders.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.